Loading clinical trials...

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

NCT03737851•AbbVie

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with relapsing Multiple Sclerosis (RMS).

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Participant has diagnosis of relapsing remitting multiple sclerosis (RRMS) or secondary-progressive multiple sclerosis (SPMS) with relapses within the past 24 months.
•Participant has cranial magnetic resonance imaging (MRI) demonstrating lesion(s) consistent with multiple sclerosis (MS).
•Participant has evidence of physical disability according to Expanded Disability Status Scale (EDSS) or Timed 25-Foot Walk (T25FW) or 9-Hole Peg Test.

Exclusion Criteria

•\- Participants must not have experienced or be recovering from a clinical MS relapse within 6 months of Screening.

Locations (49)

University of Alabama at Birmingham - Main /ID# 204618

Birmingham, Alabama, United States

St. Josephs Hospital and Med Center /ID# 204197

Phoenix, Arizona, United States

Sutter East Bay Medical Foundation-Jordon Research and Education Dev. Inst. /ID# 204249

Berkeley, California, United States

The Research Center of Southern California /ID# 204269

Carlsbad, California, United States

Vladimir Royter MD /ID# 204392

Hanford, California, United States

UC Irvine Health /ID# 205728

Irvine, California, United States

Stanford MS Center /ID# 204283

Palo Alto, California, United States

UC Davis Health-Neurological Surgery /ID# 204188

Sacramento, California, United States

UCSF School of Medicine - Neurology /ID# 204251

San Francisco, California, United States

University of Colorado School of Medicine /ID# 204250

Aurora, Colorado, United States

Key Dates

Start Date

December 11, 2018

Primary Completion Date

August 9, 2021

Completion Date

September 9, 2021

Last Updated

December 22, 2023

Enrollment

208

ACTUAL participants

Conditions

Multiple Sclerosis (MS)

Interventions

elezanumab

DRUG

placebo

DRUG

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

NCT05359653

Multiple Sclerosis (MS)Multiple Sclerosis, Relapsing-Remitting+5 more

View study

RECRUITINGNA

Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study

NCT07376772

Multiple Sclerosis (MS) - Relapsing-remittingUpper Extremity Dysfunction

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 22, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

Inclusion Criteria

Exclusion Criteria

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study

Pregnancy Cohort in Multiple Sclerosis (MS)

An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden

Educational Programs Based on Healthy Habits to Improve Quality of Life and Psychosocial Profile in Women With Neurodegenerative Diseases: The ADVICE Protocol Study (Phase 1)

Educational Programs Based on Healthy Habits to Improve Quality of Life and Psychosocial Profile in Women With Neurodegenerative Diseases: the ADVICE Protocol Study (Phase 2)